Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Prostate carcinoma and stem cells.

L M Antón Aparicio1, J Cassinello Espinosa, R García Campelo

  • 1Medical Oncology Service, CHU Juan Canalejo, Department of Medicine, University of La Coruña, 15,006-A Coruña, Spain. lantapa@canalejo.org

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|March 3, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Final overall survival results from EORTC 1333/PEACE-3 trial of enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Enzalutamide plus radium-223 in metastatic castration-resistant prostate cancer: results of the EORTC 1333/PEACE-3 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

A randomised non-comparative phase II study of atezolizumab, bevacizumab and chemotherapy in EGFR-mutant NSCLC with acquired resistance - The ETOP 15-19 ABC-lung trial.

Lung cancer (Amsterdam, Netherlands)·2025
Same author

Randomized open-label controlled study of cancer vaccine OSE2101 versus chemotherapy in HLA-A2-positive patients with advanced non-small-cell lung cancer with resistance to immunotherapy: ATALANTE-1.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

The value of disease-free survival (DFS) and osimertinib in adjuvant non-small-cell lung cancer (NSCLC): an international Delphi consensus report.

ESMO open·2022
Same journal

Circulating serum microRNAs in kidney transplant recipients with post-transplant malignancies.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026
Same journal

Multidisciplinary management of advanced ovarian cancer in Spain: expert recommendations for achieving maximum survival and improving patient care.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026
Same journal

Renal toxicity during VEGF-pathway inhibition in cancer: a practical review of proteinuria, hypertension, and kidney-limited thrombotic microangiopathy.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026
Same journal

Association of pathological response with long-term survival after neoadjuvant chemo-immunotherapy in resectable oesophageal squamous cell carcinoma: a systematic review and individual-patient-data meta-analysis.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026
Same journal

The preventable burden of tobacco-attributable cancer incidence in Catalonia (Spain) in 2024: a Bayesian approach.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026
Same journal

Concordance between multidisciplinary tumor board decisions and AI-based recommendations in endometrial cancer: impact of discordance direction on clinical outcomes.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026
See all related articles

Prostate cancer may arise from abnormal stem cell-like cells. Dysregulated Shh-Gli signaling may drive the expansion of these prostatic epithelial stem cells, leading to androgen-independent prostate cancer.

Area of Science:

  • Oncology
  • Stem Cell Biology
  • Molecular Biology

Background:

  • Stem cells possess self-renewal and differentiation capabilities, forming mature tissue cell types.
  • Cancer and stem cells share traits like infinite lifespan, self-renewal, and multidrug resistance.
  • Stem cells are implicated in the origin of various cancers, including prostate cancer.

Purpose of the Study:

  • To explore the role of stem cells in prostate cancer etiology.
  • To investigate the potential link between stem-like prostate tumor cells and androgen independence.
  • To review the involvement of Shh-Gli signaling in prostate cancer development.

Main Methods:

  • Literature review and integration of recent findings on stem cells and prostate cancer.
  • Analysis of shared characteristics between stem cells and tumor cells.

Related Experiment Videos

  • Examination of the role of Shh-Gli signaling in mammalian stem cell behavior.

    • Main Results:

    • Stem cells and tumor cells exhibit similar properties, such as self-renewal and resistance to therapies.
    • Androgen independence in prostate cancer may be associated with the emergence of stem-like tumor cells.
    • Abnormal Shh-Gli signaling is proposed to cause the overexpansion of prostatic epithelial stem cell lineages.

    Conclusions:

    • Prostate cancer may originate from the aberrant expansion of prostatic epithelial stem cell lineages.
    • Dysregulated Shh-Gli signaling is a potential driver for the development of androgen-independent prostate cancer.
    • Understanding stem cell biology is crucial for unraveling prostate cancer pathogenesis.